Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Dr. Savan Godiawala (DIN: 07874111) as an Additional Director - Non-Executive - Independent.25-04-2024
25-04-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached herewith Investors Presentation.25-04-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached Press Release.25-04-2024
Glenmark Life Sciences Ltd - 543322 - Audited Financial Results
Please Find Attached Audited Financial Results for Quarter and Year ended 31st March 202425-04-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Resignation of Director
Please find enclosed herewith Intimation of Resignation of Ms. Gita Nayyar (DIN:07128438) as a non-executive, Independent Director.22-04-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Thursday, April 25, 2024 at 4:00 p.m. - 5:00 p.m. (IST), for your information and record.19-04-2024
Glenmark Life Sciences Ltd - 543322 - Closure of Trading Window
As per the "Code of Conduct for prevention of insider trading" and pursuant to SEBI (Prohibition of Insider Trading) Regulation, 2015 the Company has intimated its directors and other designated persons regarding the closure of trading window from March 31, 2024 to April 27, 2024 (both days inclusive)for the purpose of approval of Audited Financial Results for the quarter and year ended 31st March 2024.18-04-2024
Glenmark Life Sciences Ltd - 543322 - Board Meeting Intimation for To Consider And Approve Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2024.
Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2024 ,inter alia, to consider and approve Audited Financial Results of the Company for the quarter and year ended March 31, 2024.18-04-2024
Glenmark Life Sciences Ltd - 543322 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Glenmark Life Sciences Ltd 2 CIN NO. L74900PN2011PLC139963 3 Report filed for FY 2023-2024 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2022-23,2023-24 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2022-23, 2023-24 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Rudalf CorrieaDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Tushar Mistry Designation : -Chief Financial Officer Date: 16/04/202416-04-2024
Glenmark Life Sciences Ltd - 543322 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGlenmark Life Sciences Ltd 2CIN NO.L74900PN2011PLC139963 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Rudalf Corriea Designation: Company Secretary and Compliance Officer EmailId: complianceofficer@glenmarklifesciences.com Name of the Chief Financial Officer: Tushar Mistry Designation: Chief Financial Officer EmailId: complianceofficer@glenmarklifesciences.com Date: 16/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.16-04-2024